Multiple HIV Research Achievements by Dr. Yaokai Chen’s Team from Chongqing Public Health Medical Center Was Selected for the 2023 IDWeek

2024.01.23
Editor's Note: The IDWeek in the United States is one of the largest infectious disease academic conferences globally, often referred to as the "Oscars" of the infectious disease field. Numerous cutting-edge research findings would be shared and discussed at this highly anticipated academic event. During the recent 2023 IDWeek, Dr. Yaokai Chen's team from Chongqing Public Health Medical Center had four HIV-related research findings selected for the conference. One of these was presented as a Rapid-Fire Poster, while the other three were included in poster presentations.
Dr. Thomas L. Holland：Careful consideration when selecting clinical outcomes brings more possibilities to clinical trials of bacterial diseases

Dr. Thomas L. Holland：Careful consideration when selecting clinical outcomes brings more possibilities to clinical trials of bacterial diseases

2023.11.30
Staphylococcus aureus bacteremia is a major cause of bloodstream infections, and hospital-acquired bacterial pneumonia is often caused by multidrug-resistant bacteria. And developing new antibiotics requires patient-centered clinical outcomes. How to conduct a patient-centered benefit-risk assessment in the design, analysis, and interpretation of clinical trials, so that more bacterial clinical studies can achieve the expected efficacy? At the recently Infectious Disease Week (IDWeek 2023), "Infectious Disease Frontline" invited Dr. Thomas L. Holland from Duke University Medical Center to introduce the practical application and potential challenges of DOOR research on ordinal outcome, and shared its importance to future clinical trials and treatment plans.
Dr. Chun-rong Ju: Lung Transplant Recipients Receive Prolonged Contezolid Treatment for Nocardia InfectionDr. Chun-rong Ju: Lung Transplant Recipients

Dr. Chun-rong Ju: Lung Transplant Recipients Receive Prolonged Contezolid Treatment for Nocardia InfectionDr. Chun-rong Ju: Lung Transplant Recipients

2023.11.28
Nocardia is a conditional pathogen, and infections are common in immunocompromised populations such as organ transplant recipients. Professor Chunrong Ju and her team at the First Affiliated Hospital of Guangzhou Medical University's Respiratory and Critical Care Department and Transplant Department previously reported cases of Nocardia infection in lung transplant recipients (LTR) among the East Asian population [1,2]. During the 2023 IDWeek congress, Dr. Chun-rong Ju further presented the clinical outcomes of 18 LTR Nocardia infection patients who received treatment with the novel oxazolidinone-class drugs Linezolid or Contezolid. The results indicated that these novel oxazolidinone drugs were effective during prolonged anti-infection therapy in such patients and had fewer toxic side effects, including bone marrow suppression [3].